Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

2229 - Effect of oral magnesium supplementation on the kinetics of magnesium wasting induced by EGFR targeted antibody therapy for colorectal carcinoma (MAGNET trial)


22 Oct 2018


Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care


Supportive Care and Symptom Management

Tumour Site

Colon and Rectal Cancer


Hubert Piessevaux


Annals of Oncology (2018) 29 (suppl_8): viii603-viii640. 10.1093/annonc/mdy300


H. Piessevaux1, W. Demey2, A. Bols3, J. Janssens4, M. Polus5, H. Rezaei Kalantari6, S. Laurent7, A. Demols8, Y. Humblet9, G. Deboever10, K. Kargar Samani11, M. Ferrante12, E. Monsaert13, T. Rondou14, J. van Laethem8, S. Tejpar15

Author affiliations

  • 1 Hepato-gastroenterology Dept, Cliniques Universitaires St. Luc, 1200 - Brussels/BE
  • 2 Medical Oncology Dept, A.Z. Klina, 2930 - Brasschaat/BE
  • 3 Oncology Dept, AZ St. Jan Av, 8000 - Brugge/BE
  • 4 Gastroenterology, A.Z. Turnhout, 2300 - Turnhout/BE
  • 5 Gastroenterology Dept, Centre Hospitalier Uuniversitaire Sart Tilman, 4000 - Liège/BE
  • 6 Oncology Dept, CHR Verviers, 4800 - Verviers/BE
  • 7 Gastroenterology, UZ Gent, 9000 - Gent/BE
  • 8 Gastroenterology Dept, Erasme University Hospital-(Universite Libre de Bruxelles), 1070 - Brussels/BE
  • 9 Medical Oncology, Cliniques Universitaires St. Luc, 1200 - Brussels/BE
  • 10 Gastroenterology Dept, AZ Damiaan, 8400 - Oostende/BE
  • 11 Oncology Dept, CHWAPI, 7500 - Tournai/BE
  • 12 Gastroenterology, A.Z. Sint Maarten, 2800 - Mechelen/BE
  • 13 Gastroenterology Dept, AZ Maria Middelares, 9000 - Gent/BE
  • 14 Gastroenterology Dept, St-Jozef Kliniek, 2880 - Bornem/BE
  • 15 Gastroenterology Dept, University Hospitals Leuven, 3000 - Leuven/BE


Abstract 2229


Progressive decrease of serum magnesium levels occurs in virtually all patients treated with anti-EGFR antibodies. This is supposedly linked to an inhibition of renal TRPM6 activity. This Mg loss may ultimately require stopping the anti-cancer treatment. In patients with congenital TRPM6 deficiency, high dose oral Mg supplementation allows to maintain acceptable serum Mg levels but may induce significant diarrhea. We hypothesized that oral Mg gluconate substitution may prevent and/or treat Mg wasting due to anti-EGFR treatment in colorectal cancer (CRC).


We performed a prospective randomized multi-centre trial in patients treated with anti-EGFR antibodies for CRC evaluating the efficacy and tolerability of oral Mg gluconate for prevention and/or treatment of Mg wasting. Upon initiation of anti-EGFR treatment, patients were randomized to no intervention (arm A) or Mg gluconate 3 g bid (arm B). After occurrence of hypomagnesaemia grade 1, Mg gluconate 3 g bid was initiated in arm A, whereas the dosage was increased to 3g 6 times daily in arm B. The co-primary outcome variables were the slope of the serum Mg levels since baseline and the mean number of bowel movements per day. An a priori statistical analysis plan estimated the need to screen 180 patients (β = 0.90) to demonstrate an effect on serum Mg slopes.


After excluding 7 patients during screening, 89 were randomized to arm A (no intervention) and 84 to arm B (Mg supplementation). In an ITT approach, the mean serum Mg slope was significantly (p = 0.015) steeper in arm A: -0.0045 (95%CI: -0.0062 to -0.0034) vs. -0.0021 (95%CI: -0.0037 to -0.0009) mg/dl/day in arm B. Hypomagnesaemia occurred in 12 and 4 patients respectively (p = 0.05). This lead to insufficient number of patients to draw conclusions for the second part of the trial. The mean number of bowel movements was not different across arms. Oral Mg supplementation was not associated to significant adverse events.


This prospective randomized trial demonstrated that oral Mg gluconate 3 g bid. significantly decreased Mg wasting during anti-EGFR treatment in colorectal cancer, thereby delaying the occurrence of hypomagnesemia. This treatment was well tolerated.

Clinical trial identification

EudraCT: 2007-001131-61.

Legal entity responsible for the study

Belgian Group of Digestive Oncology.


Has not received any funding.

Editorial Acknowledgement


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.